<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Alzheimer’s disease (AD) remains one of the most challenging pathologies since its etiology is not completely known, its progression is slow and there are no disease-changing pharmacological agents available yet. One other important characteristic is that the progression of AD pathology starts long before any symptoms are experienced by patients. This is where the need for early detection biomarkers comes from. Although there are biomarkers that have been intensely studied and are now included in research criteria, most of these biomarkers are either invasive or unaffordable. Blood-based biomarkers could be a viable alternative of accessible and acceptable biomarkers, and have been much studied in the past decade. Among them proteomics and lipidomics seem to be two most promising fields for biomarker development. The paper aims to offer an overview of developments in the field during the past 5 years highlighting the most promising biomarkers.</p></abstract>

Alzheimer’s disease (AD) remains one of the most challenging pathologies since its etiology is not completely known, its progression is slow and there are no disease-changing pharmacological agents available yet. One other important characteristic is that the progression of AD pathology starts long before any symptoms are experienced by patients. This is where the need for early detection biomarkers comes from. Although there are biomarkers that have been intensely studied and are now included in research criteria, most of these biomarkers are either invasive or unaffordable. Blood-based biomarkers could be a viable alternative of accessible and acceptable biomarkers, and have been much studied in the past decade. Among them proteomics and lipidomics seem to be two most promising fields for biomarker development. The paper aims to offer an overview of developments in the field during the past 5 years highlighting the most promising biomarkers.

Blood-based biomarkers in Alzheimer’s disease: an overview on proteomic and lipidomic approaches

University of Medicine and Pharmacy Tîrgu Mureş, România, Psychiatry Department

Central Military Hospital „Dr Carol Davila“, Bucharest, Romania, Psychiatry Department

Department of Adult Mental Health Inpatient, Lanchester Road Hospital, Durham, United Kingdom

Sociology and Psychiatry Faculty, „Spiru Haret“ University, Bucharest, Romania

University of Medicine and Pharmacy Tîrgu Mureş, România, Psychiatry Department Gh Marinescu 38, Tg Mures, Romania

Psyhotherapy and Personal Development Institute, Tîrgu Mureş, Romania

Revista Romana de Medicina de Laborator

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Alzheimer’s disease (AD) remains one of the most challenging pathologies since its etiology is not completely known, its progression is slow and there are no...

Blood-based biomarkers in Alzheimer’s disease: an overview on proteomic and lipidomic approaches

Pubblicato online: 28 giu 2016

Pagine: 143 - 152

Ricevuto: 16 nov 2015

Accettato: 26 mar 2016

DOI: https://doi.org/10.1515/rrlm-2016-0017

Parole chiave
blood biomarkers, Alzheimer’s disease, proteomics, lipidomics

© by Adriana Mihai

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Blood-based biomarkers in Alzheimer’s disease: an overview on proteomic and lipidomic approaches

Pubblicato online: 28 giu 2016

Pagine: 143 - 152

Ricevuto: 16 nov 2015

Accettato: 26 mar 2016

DOI: https://doi.org/10.1515/rrlm-2016-0017

Parole chiaveblood biomarkers, Alzheimer’s disease, proteomics, lipidomics

© by Adriana Mihai

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Parole chiave
blood biomarkers, Alzheimer’s disease, proteomics, lipidomics